Inari was founded in 2011 and focuses on mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, according to a Jan. 6 press release.
The acquisition is intended to complement Stryker’s neurovascular business. Inari provides solutions for VTE clot removal without the use of thrombolytic drugs.
Under the agreement terms, Stryker will commence a tender offer for all outstanding shares of common stock of Inari for $80 per share in cash. The boards of both Stryker and Inari have unanimously approved the acquisition.
The transaction is expected to close by the end of the first quarter of 2025, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
